Brief: Fortress Biotech And Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
27/07/2026 13:13
BRIEF-Fortress Biotech And Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing July 27 (Reuters) - Fortress Biotech Inc FBIO.O:
FORTRESS BIOTECH AND SUBSIDIARY URICA THERAPEUTICS ANNOUNCE CRYSTALYS THERAPEUTICS’ $130 MILLION SERIES B FINANCING
Source text: ID:nGNX3bFqdJ
Further company coverage: FBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fortress Biotech
See all newsFortress Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Fortress Biotech Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Fortress Biotech And Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
Fortress Biotech Q1 net income jumps on PRV sale
Brief: Journey Medical Corporation Secures Contract With Third Major Gpo For Emrosi